MK-8776 (SCH 900776)

製品コードS2735

MK-8776 (SCH 900776)化学構造

分子量(MW):376.25

MK-8776 (SCH 900776)は一種の選択性的なChk1阻害剤で、無細胞試験でIC50値が3nMですが、Chk1に作用する選択性はChk2に作用する選択性より500倍が高くなります。臨床2期。

サイズ 価格 在庫  
USD 264 あり
USD 466 あり
USD 1222 あり

カスタマーフィードバック(3)

  • MCF7 cells were seeded in 60 mm dishes and were pretreated with the specified inhibitor 1 h before stimulation with either vehicle or doxorubicin. Twenty-four hours after treatment, cells were collected and immunoblotted for nSMase2 and actin.

    Cell Death Dis, 2015, 6:e1947.. MK-8776 (SCH 900776) purchased from Selleck.

    (A, B) In the three TNBC cell lines, the numbers of autophagy-related spots were significantly increased in IR-alone group, and this effect was significantly suppressed by MK-8776 (IR vs MK-8776+IR: 65±23 vs 13±8, P<0.0001 in MDA-MB-231; 57±32 vs 18±7, P=0.0014 in BT-549; 43±35 vs 14±10, P=0.021 in CAL-51).

    Acta Pharmacol Sin, 2017, 38(4):513-523. MK-8776 (SCH 900776) purchased from Selleck.

  • Hela cell was trypsinized and plated at 30% confluence in DMEM. 16 hours later, MK-8776 (SCH900776) was added at final concentrations of 0, 5, 10 and 25uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using total- CHK1, pS345-CHK1 and beta-actin (internal control) antibodies.

    MK-8776 (SCH 900776) purchased from Selleck.

製品安全説明書

Chk阻害剤の選択性比較

生物活性

製品説明 MK-8776 (SCH 900776)は一種の選択性的なChk1阻害剤で、無細胞試験でIC50値が3nMですが、Chk1に作用する選択性はChk2に作用する選択性より500倍が高くなります。臨床2期。
ターゲット
Chk1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
Chk2 [1]
(Cell-free assay)
3 nM 0.16 μM 1.5 μM
体外試験

SCH 900776 is a less potent inhibitor of Chk2 and CDK2 with IC50 of 1.5 μM and 0.16 μM, respectively. SCH 900776 shows no significant inhibition of cytochrome P450 human liver microsomal isoforms 1A2, 2C9, 2C19, 2D6, and 3A4. SCH 900776 induces a dose-dependent loss of DNA replication capability 24 hours after hydroxyurea exposure. SCH 900776 enhances the γ-H2AX response of hydroxyurea, 5-fluoruracil, and cytarabine. In combination with an antimetabolite, SCH 900776 induces accumulation of γ-H2AX within 2 hours, indicative of replication fork collapse and double stranded DNA breaks. Additionally, SCH 900776 suppresses accumulation of the Chk1 pS296 autophosphorylation in a dose-dependent manner. Exposure of proliferating WS1 cells to SCH 900776 is associated with rapid, dose-dependent accumulation of Chk1 pS345, indicating that cycling populations of normal cells induce Chk1 pS345 following exposure to SCH 900776 as part of a futile cycle, perhaps driven by AT-family kinases and DNA-PK.[1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U251 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fRdFIxOC9{MECwJI5O NWHqc|JbOjRiaB?= MVHk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MkL4NlQ{PTl3Mk[=
HCT115 M1j2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fXTFIxOC9{MECwJI5O MnzHNlQhcA>? MkLP[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NXXyXJpIOjR|NUm1NlY>
SW620 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;ue|IxOC9{MECwJI5O NV3FW5B3OjRiaB?= M2jHcYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= M2PuNlI1OzV7NUK2
IGROV-1 M{TjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrHSYQzODBxMkCwNEBvVQ>? MoLWNlQhcA>? M2nPe4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= NYXvUYdoOjR|NUm1NlY>
HCT116 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTlWGljOjByL{KwNFAhdk1? NXrweFRoOjRiaB?= NVHlfYdi\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l Mnf6NlQ{PTl3Mk[=
MCF10A MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3XNlAxNzJyMECgcm0> NEfwW3czPCCq NHX4Vopl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= Mn7lNlQ{PTl3Mk[=
MiaPaCa-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSwRokzODBxMkCwNEBvVQ>? MUeyOEBp Ml\v[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n M1nwSFI1OzV7NUK2
MDA-MB-231 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzOTmEzODBxMkCwNEBvVQ>? NYf0bJFtOjRiaB?= Mn;V[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NYTqOHpVOjR|NUm1NlY>
HCC2998 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTkNlAxNzJyMECgcm0> NIWySmgzPCCq MnnP[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MXyyOFM2QTV{Nh?=
U87 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmyNFAwOjByMDDuUS=> NUTLeG5FOjRiaB?= NWnzTYRW\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NFLSR2YzPDN3OUWyOi=>
MDA-MB-435 M{fMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnFNlAxNzJyMECgcm0> MWSyOEBp M1n4WoRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MXSyOFM2QTV{Nh?=
SNB19 M{HvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLKN2VNOjByL{KwNFAhdk1? MYmyOEBp MV7k[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? M{P1S|I1OzV7NUK2
U20S MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DFPVIxOC9{MECwJI5O NUHxcW8{OjRiaB?= MYPk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? MW[yOFM2QTV{Nh?=
A498 M2rSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PCOVIxOC9{MECwJI5O NHS5T2YzPCCq MmfT[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NEK2bpEzPDN3OUWyOi=>
TK10 NXXYVnRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorsNlAxNzJyMECgcm0> MoTVNlQhcA>? MonK[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MUmyOFM2QTV{Nh?=
AsPC-1 M4TreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSyNFAwOjByMDDuUS=> MkTFNlQhcA>? M3Ts[4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= NU\GSmdMOjR|NUm1NlY>
H23 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jvSlUxOCCwTR?= MW[yOEBp NICwT3VFVVOR M2W4SoVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z M4fFNFI1OTF|NUS5
H1437 NWPSPZV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2wbGZJPTByIH7N MlfsNlQhcA>? MYHEUXNQ MoTz[Y5p[W6lZYOgeIhmKGOqZX3vd4Vve2m2aYrheIlwdiC2bzDQUXg> M2rVdFI1OTF|NUS5
H1993 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrCR5NKPTByIH7N M{XrZlI1KGh? NEfrZWRFVVOR M{DDZYVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z MXGyOFEyOzV2OR?=
H1299 NYDmPHVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS0OVAxKG6P MXuyOEBp MmLZSG1UVw>? NHT2fXJmdmijbnPld{B1cGViY3jlcY9{\W6|aYTpfoF1cW:wIITvJHBOYA>? MWGyOFEyOzV2OR?=
AsPC-1 NVHPOYNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrYVGxbOTBvMUCwNEBvVQ>? MYCyOE01QGh? NG\jNI5mdmijbnPld{B1cGViY3jlcY9{\W6|aYTpfoF1cW:wIITvJIdmdWOrdHHibY5m NUfqUJpLOjN6MES0NlI>
MiaPaCa-2 M2rMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;Ib|Q{OTBvMUCwNEBvVQ>? MXmyOE01QGh? Mlq1[Y5p[W6lZYOgeIhmKGOqZX3vd4Vve2m2aYrheIlwdiC2bzDn[Y1kcXSjYnnu[S=> NWTndZI2OjN6MES0NlI>
BxPC-3 M3S5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXrPGlsOTBvMUCwNEBvVQ>? NFfVSVMzPC12OHi= M1yxPIVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> NFjXdJAzOzhyNESyNi=>
SKOV3 NEjQTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PTblAvOyEEtV2= MWG4JIQ> NGrqelJ{\W6|aYTpfoV{KHSqZTDj[YxtKGyrbnXzJJRwKGenbXPpeIFjcW6nwrC= MU[yN|U1QDJ4OR?=
OVCAR-8 NXfnXm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfGbJAxNjNiwsXN M{LY[Fgh\A>? NEO3UVZ{\W6|aYTpfoV{KHSqZTDj[YxtKGyrbnXzJJRwKGenbXPpeIFjcW6nwrC= MlXDNlM2PDh{Nkm=
MV-4-11 NEPpXIVCeG:ydH;zbZMhSXO|YYm= MoHKNVAxNTdyMDDuUS=> NGjoUFI1QCCq MUnpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MX6yN|U{Pjd{MR?=
U937 M3jiRWFxd3C2b4Ppd{BCe3OjeR?= M2q0XFExOC15MECgcm0> NXTwOW5KPDhiaB?= M4LmNolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= M3zifFI{PTN4N{Kx
MOLM-13  MVrBdI9xfG:|aYOgRZN{[Xl? MXixNFAuPzByIH7N NXLKfVYxPDhiaB?= NFPGbIdqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MnjGNlM2OzZ5MkG=
A2058  MlHkR4VtdCCYaXHibYxqfHliQYPzZZk> NVG4SFhLOzdwNT2zNFAhdk1? NFLXdXo4OiCq NYrXUHA5TE2VTx?= M2LwbJJm\HWlZYOgeIhmKE2NLUG3O|UhTUN3MNMgZpkhPS2ob3zkJJRwKGGwIHH2[ZJi\2Vib3[gOFUhdk1? MWqyN|E1QDZ6NB?=
H2009 MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4DjNlUxOCCwTR?= MmrqO|IhcA>? NUO1U2lwTE2VTx?= NXrJS5premW|dXz0d{BqdiCJMT;TMZBp[XOnIHHjZ5VufWyjdHnvckBkd22kaX7l[EB4cXSqIF3LMVE4PzV? M3jOXVI{OTR6Nki0
Su.86.86 Mnu4R4VtdCCYaXHibYxqfHliQYPzZZk> NELRVHc2ODBibl2= MXS3NkBp NE\5[5RFVVOR MkntdoV{fWy2czDpckBIOS:VLYDoZZNmKGGlY4XteYxifGmxbjDjc41jcW6nZDD3bZRpKE2NLUG3O|U> NELF[5IzOzF2OE[4OC=>
HRE MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MljzOVAxKG6P MmHGO|IhcA>? M3\0NmROW09? M1HCSpJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 MX:yN|E1QDZ6NB?=
HMEC NFGwZWNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnS2OVAxKG6P Mn25O|IhcA>? M1LqXGROW09? MXvy[ZN2dHS|IHnuJGcyN1NvcHjhd4Uh[WOldX31cIF1cW:wIHPvcYJqdmWmIIfpeIghVUtvMUe3OS=> MX[yN|E1QDZ6NB?=
U2OS  MorYSpVv[3Srb36gRZN{[Xl? NGmwRnUzKML3TR?= M{L5UFAuOjRiaB?= NYfqSIhocW6mdXPld{BxcG:|cHjvdplt[XSrb36gc4YhS2itMTDheEB{\XKrbnWgN|Q2KGG2IHLveIgh[2:wY3XueJJifGmxboOgZZMh\WG{bImgZZMhOiCqIHHmeIVzKGGmbXnubZN1emG2aX;u NEnINpQzOjl|N{G0Oy=>
U2OS  NXjZd4ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWwMVExKML3TR?= NHXmfXczPC92ODDo NGDnTINqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M{fDPFIzQTN5MUS3
U937 NVrPOFJETnWwY4Tpc44hSXO|YYm= MlvlNVAxNTVyMDDuUS=> MWm0JIjDqA>? NUTJ[5dG\GWlcnXhd4V{KHSqZTDjfZRiemGkaX7lMYlv\HWlZXSgR4hsOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejJ7NtMgZY5lKHC{ZY\lcpR{KEOmY{K1RUBld3ewcnXneYxifGmxbh?= Ml74NlI5Pjl6Nkm=
U937 MWHGeY5kfGmxbjDBd5NigQ>? M{LZcFExOCCwTR?= NVrlXpIyPCCqwrC= NF;mc49z\X[ncoPld{B1cGViY4n0ZZJi[mmwZT3pcoR2[2WmIHnubIljcXSrb36gc4bDqDOKLYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGmwdH:gSG5C MVqyNlg3QTh4OR?=
U937 MVPGeY5kfGmxbjDBd5NigQ>? M4DZRlExOC13MECgcm0> NHzudVY1KGkEoB?= NXLyT4dwcW6mdXPld{BqdmO{ZXHz[YQheGixc4Doc5J6dGG2aX;uJI9nKEh{QWi= NVe0SWw3OjJ6Nkm4Olk>
HL-60 MofqRZBweHSxc3nzJGF{e2G7 M3rQZ|MxNzFyMD:zNFAhdk1? NIHhVHMzPCCq MVTEUXNQ M1uyUIVvcGGwY3XzJIN6fGG{YXLpcoUucW6mdXPl[EBieG:ydH;zbZM> M3XQXVIzQDZ7OE[5
ML-1 MXXBdI9xfG:|aYOgRZN{[Xl? MXOyOU82OC9zMECgcm0> NFrROIszPCCq MoPISG1UVw>? NH3ie2ZmdmijbnPld{BkgXSjcnHibY5mNWmwZIXj[YQh[XCxcITvd4l{ MkHxNlI5Pjl6Nkm=
HCT116 MWTGeY5kfGmxbjDBd5NigQ>? NXfDVVV4OSEEtV2= M{jjSVI1KGh? NXjTNIJU[WK{b3fheIV{KG:oIHPlcIwh[3mlbHWgZZJz\XO2wrC= NYT1S3hbOjJ3MUC1OlA>
U2OS NUfMbFZ7TnWwY4Tpc44hSXO|YYm= NWjRUJRSOSEEtV2= MYWyOEBp MUDhZpJw\2G2ZYOgc4Yh[2WubDDjfYNt\SCjcoLld5TDqA>? NETqb2EzOjVzMEW2NC=>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Administered 30 minutes after gemcitabine, 4 mg/kg SCH 900776 is sufficient to induce the γ-H2AX biomarker while 8 mg/kg leads to enhanced tumor pharmacodynamic and regression responses relative to gemcitabine or SCH 900776 alone. Dose escalation of SCH 900776 (16 mg/kg and 32 mg/kg) induces incremental improvements in tumor response. Importantly, doses of SCH 900776 associate with robust biomarker activation and improved tumor response are not associated with enhanced toxicity of gemcitabine on hematological parameters in BALB/c mice. [1]

お薦めの試験操作(参考用のみ)

動物試験:[1]
+ 展開
  • 動物モデル: Female nude mice injected subcutaneously with A2780 or MiaPaCa2 cells
  • 製剤: Formulated in 20% hydroxypropyl β-cyclodextrin
  • 投薬量: ~50 mg/kg
  • 投与方法: Administered intraperitoneally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 3 mg/mL (7.97 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
4% DMSO+30% propylene glycol
5 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 376.25
化学式

C15H18BrN7

CAS No. 891494-63-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870596 Completed Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia National Cancer Institute (NCI) May 2013 Phase 2
NCT00907517 Terminated Myelogenous Leukemia, Acute|Leukemia, Lymphocytic, Acute|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive|Myelogenous Leukemia, Chronic, Aggressive Phase Merck Sharp & Dohme Corp. July 2009 Phase 1
NCT00779584 Completed Hodgkin Disease|Lymphoma, Non-Hodgkin|Neoplasms Merck Sharp & Dohme Corp. October 2008 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

  • 回答:

    Our S2735 MK-8776 (SCH 900776) is R enantiomer.

Chk信号経路図

Chk Inhibitors with Unique Features

相関Chk製品

Tags: MK-8776 (SCH 900776)を買う | MK-8776 (SCH 900776) ic50 | MK-8776 (SCH 900776)供給者 | MK-8776 (SCH 900776)を購入する | MK-8776 (SCH 900776)費用 | MK-8776 (SCH 900776)生産者 | オーダーMK-8776 (SCH 900776) | MK-8776 (SCH 900776)化学構造 | MK-8776 (SCH 900776)分子量 | MK-8776 (SCH 900776)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID